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Abstract
Background: Paravalvular leak (PVL) has significant impact on long-term outcomes in patients after 
transcatheter aortic valve implantation (TAVI). This study sought to determine whether multi-slice 
computed tomography (MSCT)-guided valve selection reduces PVL after CoreValve implantation. 
Methods: The analysis encompassed 69 patients implanted with CoreValve and were divided into two 
groups. In Group I (30 patients), valve selection was based on standard procedures, in Group II (39 patients),  
on MSCT measurements. Paravalvular leak was assessed with angiography and echocardiography.
Results: Multi-slice computed tomography results influenced a change of decision as to the size 
of the implanted valve in 12 (30.9%) patients in Group II and would have caused the decision to 
change in 9 (37.5%) patients in Group I. The degree of oversizing in Group I and II was 12.8% ±  
± 7.6% vs. 18.6% ± 5.1% (p = 0.0006), respectively. The oversizing among the patients with leak 
degree of 0–1 and ≥ 2 was 18.1% ± 6.0% and 12.8% ± 7.4% (p = 0.0036). Angiographic assessment 
indicated post-procedural PVL ≥ 2 in 50% of patients in Group I and 20.5% in Group II (p = 0.01), 
while echocardiographic assessment indicated the same in 73.3% of patients in Group I and 45.6% in 
Group II (p = 0.0136). The composite endpoint occurred in 26.6% (8/30) patients in Group I vs. 5.1% 
(2/39) patients in Group II (p = 0.0118). 
Conclusions: Selecting the CoreValve device based on MSCT resulted in smaller rates of PVL and less 
frequent composite endpoint. In 1/3 of patients MSCT led to a change of the valve size. The degree of 
oversizing had a significant impact on PVL. (Cardiol J 2017; 24, 5: 467–476)
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Introduction
Transcatheter aortic valve implantation (TAVI) 
is a new, fast-developing method of treatment for 
patients with severe aortic valve stenosis, high 
surgical risk and for inoperable patients [1]. Valves 
are generally implanted surgically in patients with 
lower surgical risk [2]. One of the limitations 
of TAVI is its association with paravalvular leak 
(PVL), which in future may hamper the spread of 
the procedure to patients with low surgical risk.
Paravalvular leak occurs in most patients after 
TAVI [3, 4]. The actual percentage of PVL varies 
greatly and depends on assessment methods and 
criteria, as well as the length of post-TAVI follow-
up. PVL is usually assessed with echocardiography, 
although this method presents some limitations 
associated with the eccentric and “spray” nature 
of PVL [5]. At discharge, PVL is present in 41–94% 
of patients (of whom in up to 24% PVL is moderate 
to severe) [5]. In the first randomized TAVI trial, 
PARTNER, PVL was diagnosed in a total of 88% 
of patients, of whom 11.8–12.2% had moderate 
to severe PVL [6, 7]. PVL assessed with angio-
graphy immediately after implantation occured 
in 60.7–94.0% of patients [8–11]. Even mild PVL 
may have a negative impact on survival after TAVI 
[3, 12, 13]. 
Paravalvular leak may be caused by valve mal-
positioning, undersizing, or the presence of calcifi-
cations. Valve selection is based on measurements 
obtained from echocardiography, angiography and 
multi-slice computed tomography (MSCT). The 
importance of MSCT (in TAVI patients) in valve 
selection has been shown by many researchers who 
demonstrated that MSCT annulus measurements 
help to predict PVL [14, 15]. Moreover, appropri-
ate degree of oversizing based on aortic valve 
area may help to reduce PVL when implanting the 
balloon-expandable Edwards Sapien (ES) valve. 
Binder et al. [16] proposed an algorithm in case of 
ES valve implantation. However, the mechanisms 
of implantation of the balloon-expandable and the 
self-expandable systems are different, and neces-
sitate different algorithms. 
The aim of the study was to determine wheth-
er, compared with the standard procedure, valve 
selection based on the measurement of diameter 
calculated from the perimeter of annulus obtained 
from MSCT test reduces PVL after the implan-
tation of the self-expandable CoreValve device 
(Medtronic, Mineapolis, MN, USA). 
Methods
Initially, the retrospective analysis encom-
passed 118 patients who underwent TAVI between 
November 26, 2008 and February 4, 2014. The first 
12 patients were excluded in order to minimize the 
learning curve effect.
The exclusion criteria were: no effective im-
plantation (n = 3), implantation of a prosthesis other 
than the self-expanding CoreValve (Accurate: n = 9, 
ES: n = 28), valve-in-valve procedure (n = 3), 
valve implantation inconsistent with the schedule 
(n = 1), lack of or uninterpretable post-procedural 
aortography (n = 5). The final analysis encompassed 
69 patients with severe aortic stenosis, implanted 
with the self-expandable CoreValve prosthesis.
Until May 2011, the operators based their 
choice of valve on the available annulus measure-
ments obtained from transthoracic (TTE) and 
transesophageal (TEE) echocardiography and 
MSCT (annulus measurement in oblique sagittal 
view). Since May 2011, the choice of the implanted 
valve was based on diameter of aortic valve annulus 
calculated from its perimeter in MSCT test.
All the patients expressed their written in-
formed consent concerning TAVI procedure.
Study endpoints
The composite endpoint consisted of one or 
more of the following events: immediate procedural 
death, annulus rupture, valve migration/embolisa-
tion, coronary obstruction and PVL > 2 assessed 
with angiography. Other periprocedural and in-
hospital complications were analyzed: procedural 
mortality, TAV-in-TAV deployment, periprocedural 
myocardial infarction, cardiac pacemaker implanta-
tion. The definitions of the above-mentioned com-
plications were consistent with the Valve Academic 
Research Consortium (VARC) 2 definitions.
MSCT-assessment and valve selection
All MSCTs were performed at the Center 
and were subsequently assessed at the Medtronic 
Central Laboratory (CoreLAB) using 3mensio 
ValvesTM software (3mensio Medical Imaging BV 
Bilthoven Netherland). Retrospectively, 24 MSCT 
tests from Group I were available for repeated 
evaluation.
In all patients, MSCT was performed with 
a Siemens apparatus (Sensation 64, Siemens Medical, 
Erlangen, Germany) according to the protocol used 
at our Center.
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Next, a 10 mL bolus of non-ionic, iodine-based, 
initially of low-osmolar and finally of iso-osmolar 
contrast medium was injected into the right basilic 
vein at 4.5–5 mL/s. After calculating the delay of 
contrast enhancement in the aortic bulb, contrast-
enhanced scanning was performed with approx. 
140 mL of contrast medium at 4.5–5 mL/s. A short 
section with the aortic valve was scanned with 
retrospective electrocardiographic gating. Next, 
with the same volume of contrast agent, the rest 
of the patient’s body was examined from the base 
of the neck to 1/3 height. 
After obtaining the raw data, the valve area 
was reconstructed in the systolic and diastolic 
phase (30%, 60% and 70% of R-R intervals). Fur-
ther calculations necessary for aortic valve implan-
tation were performed at the CoreLab according to 
the protocol. The aortic root measurements were 
performed in systole — 30% of R-R interval. The 
measurements involved the annulus, the bulb, the 
ascending aorta and the left ventricular outflow 
tract (LVOT); peripheral arteries were assessed 
for vascular access. 
Until 2011, we received reports on valve 
parameters: single-plane (sagittal view) annulus 
measurements, width and height of the aortic bulb, 
sino-tubular junction size, ascending aorta, LVOT 
and the peripheral artery diameter. Since 2011, ad-
ditional data was received regarding the minimum 
and maximum annulus size and the aortic valve 
annulus perimeter.
Valve selection
The patients (n = 69) were divided into two 
groups. Group I (n = 30) was composed of patients 
in whose case the valve was selected based on an-
nulus diameter assessed by TTE, TEE and MSCT 
(sagittal view). In Group I, the valve was selected 
based on the annulus diameter and the Medtronic 
recommendations (Table 1). Group II (n = 39) en-
compassed patients in whom valve size selection 
was based on the diameter of aortic valve annulus 
calculated from its perimeter in MSCT test.
Multi-slice computed tomography-based an-
nulus perimeter served to calculate the annulus 
diameter according to the following formula: an-
nulus perimeter/3.14, assuming a round shape of 
the annulus (Fig. 1). 
The annulus diameter was also calculated 
as an arithmetic mean value of two MSCT-based 
minimum and maximum annulus diameters. The 
estimated oversizing was defined as oversizing 
of the base of the CoreValve device at the level 
of the native annulus (Fig. 2). Oversizing was 
expressed according to the arithmetical formula: 
[1 – (perimeter the base of CoreValve / perimeter 
of the annulus)] × 100 [%]. Any positive value 
was considered oversizing, while any negative 
value was considered undersizing. In reality, 
optimal valve positioning is 4–8 mm below the 
native annulus. In consideration of this and 
because of the conical shape of the CoreValve 
base, the degree of its oversizing was smaller 
than assumed (Fig. 2).
Table 1. Oversizing recommended by Medtronic.
Valve Annulus/perimeter  
— minimum
Oversizing Annulus/perimeter  
— maximum
Oversizing
26 (perimeter 81.6 mm) 20 (62.8 mm) 29.9% 23 (72.2 mm) 13.0%
29 (perimeter 91.1 mm) 23 (72.2 mm) 26.2% 27 (84.8 mm) 7.4%
31 (perimeter 97.3 mm) 26 (81.6 mm) 19.2% 29 (91.1 mm) 6.8%
Figure 1. Multi-slice computed tomography-based an-
nulus measurement.
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In Group I, valve selection was based on TTE/ 
/TEE and MSCT results, with the aortic annulus 
diameter being assessed only in sagittal view. TEE 
was performed in all but 3 patients in Group I dur-
ing TAVI, prior to valve implantation with a view to 
assess its anatomy (including the annulus size) final 
decision as to the implanted valve size was made.
Angiography-based PVL assessment 
The angiography-based PVL assessment 
was based on aortic valve insufficiency score 
proposed by Sellers et al. [17]. Aortography was 
performed after TAVI, in the same or approxi-
mately the same view as the one in which the 
valve was implanted. 20 mL of contrast medium 
were injected at 10 mL/s 450 psi. Independent 
assessment was performed by three experienced 
invasive cardiologists. Divergent opinions con-
cerned 25 (36.2%) patients; and the final decision 
was jointly made. 
Echocardiography-based PVL assessment 
The examination was performed by experi-
enced echocardiographers using the Philips iE 33 
xMATRIX and GE Vivid e9 apparatus. The diam-
eter of the aortic valve annulus was defined as the 
distance between hinge points of the aortic valve 
semilunar cusps. It was measured along the long 
axis during the final phase of ventricular systole, 
as recommended in publications [18, 19]. The 
degree of PVL was assessed by Doppler echocardi-
ography, according to the VARC I grading criteria: 
0 — absent, 1 — trace, 2 — mild, 3 — moderate, 
4 — severe. PVL was assessed by echocardiogra-
phy before discharge.
Statistical analysis 
The obtained data were presented as means 
and standard deviations (SD). To assess the statisti-
cal significance of differences between groups, two-
tailed Student’s t-test for independent variables 
was used. The Kolmogorov-Smirnov test was used 
to verify the normality of distribution and Fisher’s 
F-test to assess the equality of variance. The dif-
ferences between structure indices were assessed 
with Student’s t-test for independent samples.
Results
There were no statistically significant differ-
ences between the two groups with regard to the 
investigated clinical parameters (Table 2). 
Echocardiographic and MSCT data are pre-
sented in Table 3.
In Group I, TTE and MSCT data (one plane) did 
not differ significantly: 23.0 ± 1.9 mm vs. 23.4 ± 
2.8 mm (p = 0.2398). The same was true in Group II: 
22.9 ± 2.3 mm vs. 22.7 ± 2.4 mm (p = 0.7082). 
Although the mean TTE and MSCT measure-
ments were not significantly different, MSCT results 
influenced the change of decision as to the size of the 
implanted valve in 12 (30.9%) patients in Group II. In 
12 patients, echocardiography suggested the choice 
of a smaller valve, while MSCT (diameter calculated 
from the perimeter obtained from MSCT) pointed 
to bigger valves according to the recommendations.
Figure 2. Estimated and actual oversizing of the CoreValve self-expandable device.
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According to the recommendations in Group I, 
if the valve selection had involved the diameter 
calculated from the perimeter of valve annulus 
obtained from MSCT test, it would have been 
necessary to change the decision concerning 
implantated valves: 6 (25%) patients would have 
needed bigger valve, 1 (4.1%) patient smaller, and 
2 (8.2%) patients would have not qualified for valve 
implantation because of the annulus size.
Procedure-related data are presented in Table 4.
PVL immediately after the procedure 
Angiographic assessment immediately after 
the procedure showed that a tight valve with no 
leak was more frequent in Group II than in Group I: 
15 (38.5%) vs. 5 (16.7%) patients respectively 
(p = 0.0479). PVL of grade 3 according to Sell-
ers’ criteria was less frequent in Group II than in 
Group I: 2 (5.1%) vs. 6 (20%); however, the dif-
ference was of borderline statistical significance 
(p = 0.0552). Also PVL grade ≥ 2 was significantly 
less frequent in Group II than in Group I (Table 5). 
Post-procedural echocardiographic assessment 
also confirmed that PVL occurred significantly less 
frequently in Group II (Table 5).
The mean degree of oversizing in relation to 
leak grade 0, 1, 2, 3 was 19.0%, 17.3%, 13.9%, 
and 11.5%, respectively. Significant statistical dif-
ferences were found in oversizing among patients 
with the leak of 0th and 3rd degree (respectively 19.0 
± 5.3% vs. 11.5 ± 6.6%, p = 0.0082), 0th and 2nd 
degree (19.0 ± 5.3% vs. 13.9 ± 7.7%, p = 0.0286) 
Table 2. Patient characteristics.
Group I (n = 30) 
TTE/TEE/MSCT
Group II (n = 39) 
MSCT
P
Age [years] 77.4 ± 7.4 76.7 ± 9.3 0.7452
Male 18 (60%) 24 (61.5%) 0.8993
Body mass index 28.2 ± 3.4 28.3 ± 5.6 0.9422
Diabetes 12 (40.0%) 16 (41.0%) 0.9332
Arterial hypertension 22 (73.3%) 30 (76.9%) 0.7325
Smoking history 10 (33.3%) 17 (43.9%) 0.3715
Chronic obstructive pulmonary disease 8 (26.7%) 11 (28.2%) 0.8900
NYHA class I 1 (3.3%) 0 (0.0%) 0.2510
NYHA class II 12 (40.0%) 12 (30.8%) 0.4264
NYHA class III 16 (53.4%) 23 (59.0%) 0.6418
NYHA class IV 1 (3.3%) 4 (10.2%) 0.2717
History of cerebrovascular accident or TIA 4 (13.3%) 7 (17.9%) 0.6045
Prior coronary artery bypass graft 11 (36.7%) 13 (33.3%) 0.7688
Valve surgery 3 (10.3%) 2 (5.1%) 0.4122
Porcelain aorta 4 (13.3%) 8 (20.5%) 0.4339
Pulmonary hypertension (> 60 mm Hg) 2 (6.7%) 6 (15.4%) 0.2636
Prior implantation of a cardiac stimulator/ICD/CRT-D 11 (36.6%) 8 (20.5%) 0.1376
Prior myocardial infarction 14 (46.7%) 13 (33.3%) 0.2582
Prior balloon aortic valvuloplasty 7 (23.3%) 4 (10.3%) 0.1437
Prior PCI within the previous 3 months 6 (20.0%) 13 (17.9%) 0.8249
Non-cardiac vascular lesions 16 (53.3%) 13 (33.3%) 0.0952
Kidney failure [GFR < 60 mL/min/1.73 m2] 14 (48.3%) 20 (55.6%) 0.5472
Atrial fibrillation 5 (16.6%) 6 (12.8%) 0.6563
Standard EuroSCORE 11.3 ± 2.9 10.2 ± 2.2 0.0864
Logistic EuroSCORE [%] 26.7 ± 16.5 20.5± 10.7 0.0638
STS risk score 6.7 ± 8.2 5.6 ± 3.1 0.4302
NT-proBNP [pg/mL] 3843.7 ± 5880 3286.5 ± 6300 0.7118
CRT-D — cardiac resynchronization therapy defibrillator; GFR — glomerular filtration rate; ICD — implantable cardioverter defibrillator; 
MSCT — multi-slice computed tomography; NT-proBNP — N-terminal natriuretic propeptide type B; NYHA — New York Heart Association; 
PCI — percutaneous coronary intervention; STS — Society of Thoracic Surgeons; TIA — transient ischemic attack; TEE — transesophageal 
echocardiography; TTE — transthoracic echocardiography
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Table 3. Echocardiographic and MSCT data.
Group I (n = 30) 
TTE/TEE/MSCT
Group II (n = 39) 
MSCT
P
Echocardiographic data
Ejection fraction [%] 42.4 ± 11.2 47.0 ± 12.9 0.1210
Mean aortic transvalvular gradient [mm Hg] 50.0 ± 17.9 48.6 ± 16.6 0.7629
Annulus size in TTE [mm] 23.0 ± 1.9 22.9 ± 2.3 0.8377
Annulus size in TEE [mm] 23.7 ± 2.31 22.9 ± 2.92 0.3064
Aortic valve area [cm2] 0.60 ± 0.17 0.64 ± 0.18 0.3898
Aortic valve area index [cm2/m2] 0.35 ± 0.10 0.37 ± 0.14 0.6005
Pulmonary hypertension (> 60 mm Hg) 2 (6.7%) 6 (15.4%) 0.2636
MSCT data
Annulus size MSCT (one plane) [mm] 23.4 ± 2.8 22.7 ± 2.4 0.2415
Minimum annulus size [mm] 22.8 ± 2.3* 21.3 ± 2.3 0.0146
Maximum annulus size [mm] 27.7 ± 3.0* 26.5 ± 2.3 0.0787
Annulus perimeter [mm] 80.7 ± 6.7* 75.8 ± 6.8 0.0700
Annulus size calculated with the formula: min + max/2 [mm] 25.1 ± 2.6* 23.8 ± 2.1 0.0333
Perimeter-derived annulus size (annulus perimeter/3.14) [mm] 24.8 ± 5.2* 23.6 ± 4.1 0.3130
Degree of oversizing [%] 12.8 ± 7.6* 18.6 ± 5.1 0.0006
Number of patients in whom valve size was changed  
based on MSCT results 
12 (35.0%)
*Data from 24 patients; 127 patients; 215 patients; MSCT — multi-slice computed tomography; TTE — transthoracic echocardiography; TEE — 
transesophageal echocardiography
Table 4. Procedure-related data.
Group I (n = 30) 
TTE/TEE/MSCT
Group II (n = 39) 
MSCT
P
Anesthesia:
General 26 (86.7%) 17 (43.6%) 0.0431
Local 4 (13.3%) 17 (43.6%) 0.1332
Local with conversion to general 0 (0%) 5 (12.8%) 0.2422
Access:
Transfemoral 21 (70.0%) 28 (71.8%) 0.8702
Transsubclavian 8 (26.7%) 10 (25.6%) 0.9178
Transaortic 1 (3.3%) 1 (2.6%) 0.8637
Percutaneous 8 (26.7%) 18 (46.2%) 0.0976
Surgical 22 (73.3%) 21 (53.8%) 0.0976
Valve size:
26 8 (26.7%) 12 (30.8%) 0.7030
29 16 (53.3%) 17 (43.6%) 0.4239
31 6 (20.0%) 10 (25.6%) 0.5847
Balloon postdilatation 3 (10.0%) 8 (20.5%) 0.2375
Implantation depth [mm] — angiographic assessment 5.9 ± 3.57 5.8 ± 3.78 0.9523
Number of proctored procedures 21 (70%) 0 (0%) < 0.001
MSCT — multi-slice computed tomography; TTE — transthoracic echocardiography; TEE — transesophageal echocardiography
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and patients with the leak of 0th–1st and ≥ 2nd degree 
(18.1 ± 6.0% vs. 12.8 ± 7.4%, p = 0.0036). The 
degree of oversizing differed significantly between 
Group I and II and was, respectively, 12.8 ± 7.6% 
vs. 18.6 ± 5.1%, p = 0.0006 (Table 3).
Clinical course after TAVI
There were 3 (10%) in-hospital deaths in 
Group I and 1 (2.6%) in Group II. One of the three 
deaths in Group I was caused by heart failure at-
tributable to PVL grade 3. Another patient devel-
oped septic shock and multiple organ dysfunction 
syndrome. In that patient, TAVI was performed in 
a very poor clinical condition following an earlier 
valvuloplasty. The third patient died due to cardiac 
tamponade during CRT-D implantation several 
days after TAVI.
In Group II, 1 patient with a moderate leak died 
due to post-operative vascular complications. No 
annulus rupture, valve dislocation, or coronary flow 
limitation occurred in either group. The composite 
endpoint occurred in 8 patients in Group I and 2 in 
Group II (p = 0.0118). The percentages of neces-
sary implantation of cardiac stimulation systems 
were similar in both groups (Table 6).
Discussion
The impact of PVL on the outcome has been 
reported in a number of recent publications. Based 
on their PARTNER randomized trial, Kodali et 
al. [3] proved that even a mild PVL following the 
implantation of a balloon-expandable valve affects 
3-year survival. Schewel et al. [12] also showed 
that PVL ≥ 2+ in patients after implantation of 
self-expandable and balloon-expandable heart 
valves was associated with a considerable increase 
in 6-month mortality and a significant increase in 
N-terminal natriuretic propeptide type B levels. 
Hayashida et al. [13] concluded that even PVL = 2 
negatively affects the outcome for both CoreValve 
and ES devices. PVL is attributable to numerous 
factors, mainly the presence of calcifications, 
depth of valve implantation, the angle between 
the LVOT and the aorta, and valve undersizing 
[8, 11, 12, 20–23]. 
This study demonstrates that valve selection 
based on the measurements of diameter and an-
nulus perimeter obtained from MSCT test may in-
crease the percentage of tight CoreValve implanta-
tions and reduce the percentage of significant leaks 
in comparison to the standard procedures. It also 
presents one of the highest rates of patients with 
no leak after CoreValve implantation published so 
far [5]. Valve perimeter was chosen as the base 
for calculation of the annulus diameter because it 
had less variability across the cardiac cycle, which 
gives a more precise reading than area measure-
ments [15]. Also, because of the fact that CoreValve 
adapts itself to the annulus of the native valve, 
the calculation of perimeter is more useful here. 
In the work of Von Aspern et al. [24] the diameter 
Table 5. Paravalvular leak in angiographic and echocardiographic assessment.
Group I (n = 30) 
TTE/TEE/MSCT
Group II (n = 39) 
MSCT
P
PVL in angiographic assessment
0 5 (16.7%) 15 (38.5%) 0.0479
1 10 (33.3%) 16 (41.0%) 0.5128
2 9 (30%) 6 (15.4%) 0.1450
3 6 (20%) 2 (5.1%) 0.0552
4 0 (0%) 0 (0%) NS
≥ 2 15 (50%) 8 (20.5%) 0.0100
PVL assessed with echocardiography
Absent 6 (20.0%) 9 (23.1%) 0.7570
Trace 2 (6.7%) 13 (33.3%) 0.0079
Absent/trace 8 (26.7%) 22 (56.4%) 0.0136
Mild 15 (50.0%) 13 (33.3%) 0.1614
Moderate 6 (20.0%) 4 (10.6%) 0.2742
Severe 1 (3.3%) 0 (0%) 0.2532
MSCT — multi-slice computed tomography; TTE — transthoracic echocardiography; TEE — transesophageal echocardiography
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calculated from the surface area of the valve was 
smaller than the diameter calculated from the pe-
rimeter in MSCT test. In case of balloon-expanded 
valve, the valve adjusts the native annulus to its 
round shape. In this case it is more appropriate to 
calculate the diameter of annulus from the surface 
area of the valve.
The main disadvantage of MSCT valve meas-
urement is the fact that in some patients the qual-
ity of the examination is not sufficient for reliable 
measurements. In the present study, this was the 
case in 15.2% of patients. Factors affecting quality 
of the examination include heart rate, heart rhythm 
disorders and obesity.
What were the deciding factors for better 
valve adjustment and smaller PVL in Group II? 
TTE, TEE and MSCT examinations determined the 
aortic annulus size in one dimension only and may 
be adequate only in cases of round-shaped aortic 
valves. According to Schultz et al. [25] though, the 
aortic valve is round in 50% of cases. In patients 
with elliptic valves, two measurements are avail-
able: minimum and maximum. In such situations, 
decisions based on measuring only one dimension, if 
it is the smaller dimension, tend to lead to the selec-
tion of a smaller valve and the occurrence of PVL.
In this study, echocardiography measurements 
yielded smaller values than those from MSCT. 
TTE and MSCT (one plane) results did not differ 
significantly. Most probably, this ambiguous results 
were due to the small size of the investigated 
groups. The less frequent occurrence of PVL was 
determined by the change in decision regarding 
valve size selection based on the measurement 
of annulus diameter based on perimeter obtained 
from MSCT test in comparison with the measure-
ment of the annulus diameter using TTE. This 
concerned 30.9% of patients in Group II, and all 
cases which involved a change to a larger valve. 
Retrospective analysis of MSCT images in Group I 
showed that as many as 37.0% (9/24) should have 
received a different size of valve. Similar conclu-
sions have been reached by Mylotte et al. [26]. 
He found that in patients who received a valve on 
the basis of measurements performed using TEE, 
MSCT showed that CoreValve devices exhibited 
low degree of oversizing (10.1 ± 8.6%). He also 
stated that choosing the valve on the basis of 
measurements of the annulus diameter obtained 
from MSCT may prompt the decision to change 
the previously selected valve for as many as 50% 
of patients. Hayashida et al. [13] studied a group of 
175 patients who had both CoreValve and ES valves 
implanted on the basis of annulus measurements 
performed using MSCT and found that the annu-
lus diameter and the median size of the implanted 
valves were bigger in comparison to a group of 
patients who had valves selected on the basis of 
TEE measurements. Moreover, in 34 (18.5%) pa-
tients MSCT test led to a decision to change the 
valve size. For all patients, except one, the change 
involved implanting a bigger valve.
This study does not give clear indications as 
to the degree of oversizing at which the absence 
Table 6. Clinical course.
Group I (n = 30) 
TTE/TEE/MSCT
Group II (n = 39) 
MSCT
P
Immediate procedural death 0 0 NS
Procedural mortality 3 (10%) 1 (2.6%) 0.1930
Annular rupture 0 0 NS
Valve migration/valve embolisation 0 0 NS
Coronary obstruction 0 0 NS
TAV-in-TAV deployment 0 0 NS
Perioperative infarction 0 0 NS
Implantation of a cardiac stimulation system 9 (30%) 10 (25.6%) 0.6850
DDDR 6 (23.0%) 9 (23.1%) 0.9922
VVIR 2 (6.7%) 0 (0%) 0.1009
CRT-D 1 (3.3%) 1 (2.6%) 0.8637
PVL ≥ 2+ in angiographic assessment 6 (20%) 2 (5.1%) 0.0552
Composite endpoint 8 (26.6%) 2 (5.1%) 0.0118
CRT-D — cardiac resynchronization therapy defibrillator; DDDR — dual chamber rate adaptive pacemaker; MSCT — multi-slice computed 
tomography; PVL — paravalvular leak; TTE — transthoracic echocardiography; TEE — transesophageal echocardiography; VVIR — single 
chamber sensor-based, rate-modulating pacemaker
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of PVL can be expected. It was however, shown 
that there was a statistically significant difference 
in valve oversizing in Group I and II. In Group II, 
where valve adjustment was bigger,  oversizing 
was bigger as well. Additionally, statistically sig-
nificant differences were found in the degree of 
valve oversizing in patients with different degrees 
of PVL. In general, the lower the leak, the greater 
the oversizing. Mylotte et al. [26] determined the 
minimal valve oversizing as 9.0% and 9.6% for 26 
and 29 CoreValve, respectively. Buzatti et al. [27] 
showed that, in general, oversising of 7% reduced 
PVL risk, in cases of ES valve that value is 2%, 
and in case of CoreValve — 11%. Detaint et al. [22] 
concluded that for ES valve PVL does not occur 
when the degree of oversizing was greater than 8%. 
Leber et al. [23] stated that PVL occurs most rarely 
when ES valve oversizing was > 25% of the surface 
area of valve annulus. Nevertheless, such oversiz-
ing was connected with higher risk of necessity 
of pacemaker implantation. They considered the 
oversizing to the degree of 15–25% over the valve 
surface area or 7–12% over the diameter of valve 
annulus to be optimal. The concerns regarding 
the degree of oversizing requires further studies.
Nevertheless, based on the results of this 
study, it was determined that the valve selection 
based on the diameter calculated from MSCT can 
offer a high level of valve tightness. 
Limitations of the study
The limitation of this study is the single-center 
character. According to the authors, the potential 
impact of the learning curve has been limited by not 
including the first 12 patients with TAVI and also by 
the fact that 70% of the procedures were overseen 
by experienced cardiologists–proctors who had 
access to the results of ultrasound, angiography 
and MSCT examinations and the authors relied 
on their experience in selecting the valve size. In 
Group II, none of the procedures were proctored.
Conclusions
The selection of a CoreValve device based 
on MSCT measurement resulted in a smaller 
percentage of PVL, better valve adjustment and 
a lower incidence of composite endpoint. In almost 
1/3 of patients valve size changes were made. The 
degree of oversizing had a significant influence on 
paravalvular leak.
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